- Home
- APLT vs BOW Comparison
APLT vs BOW Comparison
Compare APLT & BOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- BOW
- Stock Information
- Founded
- APLT 2016
- BOW 2020
- Country
- APLT United States
- BOW United States
- Employees
- APLT N/A
- BOW N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- BOW Property-Casualty Insurers
- Sector
- APLT Health Care
- BOW Finance
- Exchange
- APLT Nasdaq
- BOW Nasdaq
- Market Cap
- APLT 971.6M
- BOW 880.2M
- IPO Year
- APLT 2019
- BOW 2024
- Fundamental
- Price
- APLT $8.69
- BOW $33.51
- Analyst Decision
- APLT Strong Buy
- BOW Hold
- Analyst Count
- APLT 5
- BOW 5
- Target Price
- APLT $12.50
- BOW $31.40
- AVG Volume (30 Days)
- APLT 1.8M
- BOW 350.3K
- Earning Date
- APLT 11-07-2024
- BOW 11-05-2024
- Dividend Yield
- APLT N/A
- BOW N/A
- EPS Growth
- APLT N/A
- BOW 130.44
- EPS
- APLT N/A
- BOW 1.08
- Revenue
- APLT N/A
- BOW $389,135,000.00
- Revenue This Year
- APLT N/A
- BOW N/A
- Revenue Next Year
- APLT $3,169.03
- BOW $31.08
- P/E Ratio
- APLT N/A
- BOW $31.03
- Revenue Growth
- APLT N/A
- BOW 107.43
- 52 Week Low
- APLT $1.79
- BOW $22.14
- 52 Week High
- APLT $10.62
- BOW $34.49
- Technical
- Relative Strength Index (RSI)
- APLT 46.34
- BOW N/A
- Support Level
- APLT $9.44
- BOW N/A
- Resistance Level
- APLT $10.62
- BOW N/A
- Average True Range (ATR)
- APLT 0.62
- BOW 0.00
- MACD
- APLT -0.13
- BOW 0.00
- Stochastic Oscillator
- APLT 14.95
- BOW 0.00
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About BOW Bowhead Specialty Holdings Inc. Common Stock
Bowhead Specialty Holdings Inc is engaged in providing specialty P&C products. It is a specialty insurance group that generates revenues by underwriting and offering a variety of specialty insurance products to domestic markets through three distinct underwriting divisions: Casualty, Professional Liability and Healthcare. Casualty specialize in GL coverage for risks in the construction, distribution, heavy manufacturing, real estate and hospitality segments and also consider underwriting risks in a broader range of industries. Key revenue is generated from Casualty segment.